<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715114</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-C1826</org_study_id>
    <nct_id>NCT03715114</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Pharmacokinetics of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Subjects</brief_title>
  <official_title>A Double-blind, Randomized, Placebo Controlled Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Sodium Oligo-mannurarate (GV-971) Capsule in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Greenvalley Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Greenvalley Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetics of GV-971 capsules after oral a single or
      multiple doses of 900 mg, 1200 mg and 1500 mg in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>2 day and 7 day</time_frame>
    <description>Cmax will be determined after oral 900 mg, 1200 mg and 1500 mg of GV-971</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life time (T1/2)</measure>
    <time_frame>2 day and 7 day</time_frame>
    <description>T1/2 will be determined after oral 900 mg, 1200 mg and 1500 mg of GV-971</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>2 day and 7 day</time_frame>
    <description>AUC will be determined after oral 900 mg, 1200 mg and 1500 mg of GV-971</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the peak drug concentration (Tmax)</measure>
    <time_frame>2 day and 7 day</time_frame>
    <description>Tmax will be determined after oral 900 mg, 1200 mg and 1500 mg of GV-971</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>7 days</time_frame>
    <description>AE occurred after oral 900 mg, 1200 mg and 1500 mg of GV-971</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>GV-971 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GV-971 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GV-971 1500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1500 mg oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GV-971</intervention_name>
    <description>Oral GV-971</description>
    <arm_group_label>GV-971 1200 mg</arm_group_label>
    <arm_group_label>GV-971 1500 mg</arm_group_label>
    <arm_group_label>GV-971 900 mg</arm_group_label>
    <other_name>Sodium Oligo-mannurarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy subjects;

          2. Age：≥18 and ≤40 on the date signing informed consent;

          3. Body mass index (BMI): 19-26 kg/m2 and the weight ≥50 kg for male and ≥45 kg for
             female；

          4. Subjects are able to understand the study procedures and methods, and willing to
             strictly comply with the protocol and give written informed consent.

        Exclusion Criteria:

          1. Subjects may be allergic to GV-971 in the opinion of the investigator;

          2. With diseases which could impact on the absorption, distribution, metabolism and
             excretion (ADME) of study drugs or protocol adherence in the opinion of the
             investigator (such medical disorder/disease may relate to cardiovascular, liver,
             kidney, digestive, immune, blood, endocrine, metabolic, cancer, neuropsychiatric,etc
             );

          3. Blood donation of ≥400 mL or severe blood lose and the volume of blood loss ≥400 mL
             within 12 weeks prior to screening;

          4. Participation in any investigational drug or medical instrument study within 3 months
             prior to screening;

          5. Use of any prescription medicine or herbal remedy, over the counter medication or
             dietary supplements such as vitamin, calcium within 2 weeks prior to screening;

          6. Smoking more than 10 cigarettes a day, drugs or alcohol abuse within 6 months prior to
             screening;

          7. Use of heparin, alginic sodium diester , mannose ester within 4 weeks prior to
             screening；

          8. Clinically significant abnormalities in physical examination and laboratory test
             results or 12-lead ECG, etc. in screening;

          9. Clinically significant abnormalities in Chest X-ray or abdominal B-ultrasound
             examination;

         10. Positive seurology screen for Hepatitis B( HBsAg), Hepatitis C(HCV), HIV and USR
             unheated serum reagin test;

         11. Vegetarian or person with dietary restrictions;

         12. Subjects able to father a child are unwilling to use highly effective physical form of
             birth control from the trial period until 3 months after the completion of study;

         13. Any other reasons that the subject is not eligible for participation in the study in
             the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Xuhui Center hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianliang Xin, Ph D</last_name>
    <phone>+86-21-50504988</phone>
    <phone_ext>1097</phone_ext>
    <email>xinxianliang@gv-ri.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phase-I Clinical Research Unit at Shanghai Xuhui Center hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Yu, MD</last_name>
      <phone>+86-21-54036058</phone>
      <email>clab001@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

